Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 July 2021 | Story Lunga Luthuli | Photo Supplied
Fletcher Hiten, Chief Bioanalyst at FARMOVS, next to Aurora.

The Bioanalytical Services Division (BASD) at FARMOVS comprises a group of skilled and passionate scientists involved in the quantification of drugs, metabolites, and biomarkers in various biological matrices. One of their Analytical Science experts, Fletcher Hiten, explains what sets their team apart from the rest.

“Over the past 47 years, we have developed almost 600 validated assay methods. Most of these methods are for the analysis of ‘small’ molecules using chromatographic techniques such as LC-MS/MS, GC-MS, and HPLC, although LC-MS/MS is the technique of choice. New bioanalytical assays are continuously being development and validated in adherence to international regulatory guidelines set by the US-FDA and European Medicines Agency (EMA),” says Hiten.

“Recently, we decided to enhance our capabilities by recruiting exceptional talent. The newest member of the FARMOVS team is Aurora, a SCIEX Triple Quad™ 7500 LC-MS/MS mass analyser. Aurora is Latin for ‘dawn’: the beginning of a new era, especially one considered favourable. The SCIEX 7500 is currently marketed as the most sensitive triple quadrupole mass spectrometer available, allowing for sub-picogram/ml quantification. This means that Aurora will set FARMOVS apart from other clinical research organisations (CROs), creating an exciting and favourable landscape for clients to explore new partners in research.” 

Hiten stated: “If there was ever a time to move your next study to FARMOVS, it is now. To have Aurora on our team has many advantages, given that our clients can access unprecedented analytical sensitivity, which enables the quantification of pharmacokinetic (PK) profiles of drugs that have very low systemic absorption. These include predominantly local acting drugs, such as plasma concentrations of respiratory drugs (e.g., tiotropium and ipratropium), topically applied creams and ointments, and ophthalmology drops with ultra-sensitivity.”

“In addition, the quantification of drugs in low-volume matrices will also be exponentially enhanced, enabling the quantification of body fluids, where only a few microlitres can be collected, for example vaginal fluid, dried blood spots, cerebrospinal fluid, aqueous humour, synovial fluid, and epidermal micro-dialysis lysate – to name a few. The quantification of absorbed exogenous drugs into tissue, like vaginal biopsies and hair follicles, is also possible,” added Hiten. 

“And finally, multiple analyte analysis. In this case, the collected blood sample needs to be split into multiple aliquots for analysis, for example drug-drug interaction (DDI) studies with the Basel cocktail. The smaller sample volumes will allow more frequent sampling to be feasible and thus more accurate DDI interpretation,” Hiten explains.

“As a bio-analyst, one is seldom surprised. However, Aurora has already opened doors to new frontiers for our entire team and we cannot wait to do some more exploration,” says Hiten. 

To find out more about what Aurora and the FARMOVS team can do for your study, email business@farmovs.com

News Archive

Justin J. Kennedy leads new Programme in Personal Excellence
2012-05-08

 

Justin J. Kennedy
Photo: Leatitia Pienaar
8 May 2012

Justin J. Kennedy has been appointed as the Manager of the new Programme in Personal Excellence. The programme is hosted in the Centre for Business Dynamics, the commercial unit of the Business School.

He studied at Rhodes University and the University of the Western Cape (UWC) and his research has been published in various health-related publications. His D.Psych. at the University of California migrated into a Ph.D. with research partner DiscoveryHealth.

While in New York, he was part of the research laboratory Helicor that developed the world’s first hand-held medical device for measuring heart-rate variability of the peripheral nervous system.  This device forms part of the programmes offered to control stress and improve cognitive performance as per clinical trials at the UCT Department of Human Biology. This programme evolved into developing the M.Sc. course work on occupational stress and Ph.D. student supervision.

The programme will launch during the university's Beneficiary Programme for Academic Heads of Department, and will focus on the neuro-economics of stress resilience.

Justin’s most recent research is peer review for an international leadership journal where he has presented evidence on how people can improve their cognitive performance and working memory by building functional stress resilience. The overall aim of the programme is to not only reduce stress, but to improve ability to be excellent at work.  Clinical results have shown it is beneficial for performance anxiety, insomnia, migraine, hypertension control and improved ability at cognitive tasks.  The aim of his work is to ensure that simple and practical skills provide academics, students and corporate participants with enduring, functional techniques that are easily applied in their working lives.

The programme has three roles: to offer services that equip students and academics; consulting services to corporate clients, financial groups and private hospitals; and publication of results in peer-reviewed journals. 

This initiative also envisages offering a postgraduate qualification and selected coaching qualifications.  For more info about corporate interventions and programmes open to students and academics, please contact Ansie Barnard at barnardam@ufs.ac.za.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept